Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients

Japanese Journal of Clinical Oncology

Volumn 36, Issue 8, 2006, Pages 477-482

  Fujisaka, Yasuhito ^a   Tamura, Tomohide ^a   Ohe, Yuichiro ^a   Kunitoh, Hideo ^a   Sekine, Ikuo ^a   Yamamoto, Noboru ^a   Nokihara, Hiroshi ^a   Horiike, Atsushi ^a   Kodama, Tetsuro ^a   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Anemia; Epoetin beta; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ERYTHROPOIETIN; FERRITIN; FERROUS SULFATE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; IRON; LACTATE DEHYDROGENASE; PHOSPHORUS; RECOMBINANT ERYTHROPOIETIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BONE MARROW SUPPRESSION; CANCER PATIENT; CARDIOMEGALY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ERUPTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FERRITIN BLOOD LEVEL; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERVENTILATION; HYPONATREMIA; INSOMNIA; IRON BLOOD LEVEL; IRON THERAPY; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LIVER DYSFUNCTION; LUNG CANCER; MALE; NAUSEA; NECK PAIN; OPEN STUDY; PHARMACODYNAMICS; SINGLE DRUG DOSE; THROMBOCYTOPENIA; VERTIGO; VOMITING; XEROSTOMIA;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; CARCINOMA, LARGE CELL; CARCINOMA, SQUAMOUS CELL; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FERRITINS; HEMOGLOBINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 33750115320     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl074     Document Type: Article

References (15)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91:1616-34.
2. Ludwig H. Epoetin in cancer-related anaemia. Nephrol Dial Transplant 1999;14[Suppl 2]:85-92.
3. Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 2002;87:1209-21.
4. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group J Clin Oncol 1998;16:3412-25.
5. Cella D, Zagari MJ, Vandoros C, Gagnon DD, Hurtz HJ, Nortier JWR. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003;21:366-73.
6. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-107.
7. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-82.
8. Ozguroglu M, Arun B, Demir G, Demirelli F, Mandel NM, Buyukunal E, et al. Serum erythropoietin level in anemic cancer patients. Medical Oncology 2000;17:29-34.
9. Charuruks N, Limpanasithikul W, Voravud N, Sutheesophon K. Erythropoietin level and hematologic parameters in healthy adults. J Med Assoc Thai 2000;83:1267-73.
10. Yamazaki C, Watanabe Y, Sakamoto N. Pharmacokinetic study of recombinant human erythropoietin treatment in pre-dialysis end stage renal disease patients. Japanese J Nephrol 1993;35:1233-42.
11. Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, Mcguire EM, Widness JA. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: Evidence for bone marrow as a major erythropoietin elimination pathway. J Pharamcol Exp Ther 2001;298:820-4.
12. Piroso E, Allan JE, Jaime C. Inappropriate increase in erythropoietin titers during chemotherapy. Am J Hematol 1989;32:248-54.
13. Sawabe Y, Kikuno K, Iseki T, Iida S, Tabata Y, Yonemitsu H. Changes in serum erythropoietin and the reticulocyte count during chemotherapy for leukemias. Eur J Haematol 1996;57:384-8.
14. Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 2002;69:265-74.
15. Sakai H, Ohashi Y, Hirashima Y, Saijo N. Japan Erythropoietin Study Group. Once weekly epoetin beta to increase hemoove quality of life in anemic cancer patients receiving chemotherapy. Meeting proceedings of the American Society of Clinical Oncology 2004;23:767.